Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma

Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma

“…These results are in good agreement with the findings of studies in adults 10,11,24 and an earlier study in children. 9 However, in contrast to the earlier studies, the present study included outcomes such as bronchial hyperresponsiveness and different definitions of asthma control, which are normally thought to be sensitive outcome measures for the detection of differences between various treatments.…”

“…[8][9][10][11][12][13] Furthermore, ciclesonide was well tolerated in these populations. 8,9,[14][15][16][17][18][19] An earlier comparison of ciclesonide versus fluticasone propionate in children, using only one dose of each drug indicated similar efficacy of the two drugs.…”

Comparative efficacy of inhaled ciclesonide, budesonide, and fluticasone in mild to moderately persistent bronchial asthma

“…But at the end of 6 th month, there was a marked improvement in PFER seen in all the three groups. [9][10][11][12] Initially, the mean FEV1% predicted was 64.1%, 60.1%, and 60.5% for the groups put on ciclesonide, budesonide, and fluticasone, respectively, and the percentage of improvement after bronchodilatation was 20%, 19%, and 21%, respectively, which markedly improved after 6-month treatment and is comparable to the study under taken by Burke et al 1991. 13 Thus, showing significant improvement in the mean values at the end of the treatment, which is comparable to the study by Buhl et al (2006).…”

Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids

“…Of the 150 patients with asthma, during the study period, 63 were treated with inhaled fluticasone propionate (FP; Flutide; GlaxoSmithKline, Tokyo, Japan), 63 with inhaled budesonide (BUD; Pulmicort; AstraZeneca, Osaka, Japan), eight with inhaled hydrofluoroalkane beclomethasone dipropionate (BDP; Qvar; Schering-Plough, Tokyo, Japan), eight with inhaled salmeterol/ FP (Seretide; GlaxoSmithKline), six with inhaled hydrofluoroalkane ciclesonide (CIC) (Alvesco; Teijin Pharma, Tokyo, Japan) and two with inhaled chlorofluorocarbon BDP (Aldecin; Schering-Plough). The daily dose of ICS was adjusted to an equipotent dose: with the dose of chlorofluorocarbon BDP as reference, the conversion factors used to calculate equipotent doses were 1.25 for BUD and 2.0 for FP, hydrofluoroalkane BDP and hydrofluoroalkane CIC [17][18][19].…”